The trial is testing the scaffold’s ability to treat spinal cord injuries. According to the changes submitted to the FDA, InVivo wants to increase resources to the trial that were previously allocated for its hydrogel drug delivery platform.
More Articles on Devices:
Global Minimally Invasive Surgery Market to Reach $50.6B by 2019
Globus Medical Receives Spinal Fixation Patent
Alphatec Holdings Names Mike Plunkett as COO
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
